Prospective Promising Signs of Herd Iimmunity in COVID-19 Transmission Suppression via Vaccination

Prospective Promising Signs of Herd Iimmunity in COVID-19 Transmission Suppression via Vaccination

Bayode, Michael Tosin

Contact

Bayode

Contact

Michael Tosin

Contact

Prospective Promising Signs of Herd Iimmunity in COVID-19 Transmission Suppression via Vaccination

Article Fingerprint

ReserarchID

Q38Y8

Prospective Promising Signs of Herd Iimmunity in COVID-19 Transmission Suppression via Vaccination Banner

AI TAKEAWAY

Connecting with the Eternal Ground

Abstract

Reports of the COVID-19 pandemic show an elevated level of mortality among patients, with some inclining hazards distinguished as age, underlying infection conditions; hypertension, diabetes, and so on, immune-compromised conditions and viral dose during exposure. Different investigations portray an elevated level of super-spreading occasions, which proposes that heterogeneity in infectivity may altogether affect the elements of its transmission. This review is intended to make the perception herd immunity needs to play in COVID-19 transmission concealment inferable from its circumspect viability for the destruction of numerous maladies and indeed, give the premise to vaccines and their applications serving as a proviso for immune individuals that will prompt a huge decrease in disease event and spread. On account of the ebb and flow of the COVID-19 scourge, this may give the perfect viewpoint to totally eradicate the illness in our local communities in the event that a vaccine is before long evolved.

References

60 Cites in Article

Reference Format

N Chen,M Zhou,X Dong,J Qu,F Gong,Y Han (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study.
Kenji Mizumoto,Katsushi Kagaya,Alexander Zarebski,Gerardo Chowell (2020). Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.
Yongjian Wu,Cheng Guo,Lantian Tang,Zhongsi Hong,Jianhui Zhou,Xin Dong,Huan Yin,Qiang Xiao,Yanping Tang,Xiujuan Qu,Liangjian Kuang,Xiaomin Fang,Nischay Mishra,Jiahai Lu,Hong Shan,Guanmin Jiang,Xi Huang (2020). Prolonged presence of SARS-CoV-2 viral RNA in faecal samples.
Wwc Topley,G Wilson (1923). The spread of bacterial infection. The problem of herd-immunity.
P Fine (1993). Herd immunity: History, theory, practice.
Harunor Rashid,Gulam Khandaker,Robert Booy (2012). Vaccination and herd immunity.
P Fine,K Eames,D Heymann (2011). "Herd Immunity": A Rough Guide.
David Smith,Herd,Immunity (2019). Herd Immunity.
G Goncalves (2008). Herd immunity: Recent uses in vaccine assessment.
M Korppi (2018). Universal pneumococcal vaccination provides marked indirect beneficial effects through herd immunity.
L Nymark,T Sharma,A Miller,U Enemark,U Griffiths (2017). Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used.
M Ali,F Qadri,D Kim,T Islam,J Im,F Ahmmed (2019). Unmasking herd protection by an oral cholera vaccine in a cluster-randomized trial.
Ryo Kinoshita,Hiroshi Nishiura (2016). Assessing herd immunity against rubella in Japan: a retrospective seroepidemiological analysis of age-dependent transmission dynamics.
Isabella Albuquerque,Renato Marandino,Aline Mendonça,Rita Nogueira,Pedro Vasconcelos,Leopoldino Guerra,Beatriz Brandão,Ana Mendonça,Guilherme Aguiar,Paula Bacco (2012). Chikungunya virus infection: report of the first case diagnosed in Rio de Janeiro, Brazil.
Kin Kwok,Florence Lai,Wan Wei,Samuel Wong,Julian Tang (2020). Herd immunity – estimating the level required to halt the COVID-19 epidemics in affected countries.
Elizabeth Miller,Nicholas Andrews,Pauline Waight,Mary Slack,Robert George (2011). Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.
G Khandaker,H Marshall,E Peadon,Y Zurynski,D Burgner,J Buttery,M Gold,M Nissen,E Elliott,M Burgess,R Booy (2011). Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia.
Mark Loeb,Margaret Russell,Lorraine Moss,Kevin Fonseca,Julie Fox,David Earn,Fred Aoki,Gregory Horsman,Paul Van Caeseele,Khami Chokani,Mark Vooght,Lorne Babiuk,Richard Webby,Stephen Walter (2010). Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities.
Ben Lopman,Daniel Payne,Jacqueline Tate,Manish Patel,Margaret Cortese,Umesh Parashar (2012). Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011.
J Fox,L Elveback,W Scott,L Gatewood,E Ackerman (1971). Herd immunity: Basic concept and relevance to public health immunization practices.
Tanu Singhal (2020). A Review of Coronavirus Disease-2019 (COVID-19).
X Peng,X Xu,Y Li,L Cheng,X Zhou,B Ren (2020). Transmission routes of 2019-nCoV and controls in dental practice.
G Zhou,Q Zhao (2020). Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.
J Xun,L Lu,S Jiang,H Lu,Y Wen,J Huang (2020). Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 2 patient cohort and their implications.
H Randolph,L Barreiro (2020). Herd immunity: Understanding COVID-19.
(2008). WHO) guide for standardization of economic evaluations of immunization programmes.
T John,Reuben Samuel (2000). Herd immunity and herd effect: new insights and definitions.
Richard Adegbola,Ousman Secka,George Lahai,Nellie Lloyd-Evans,Alpha Njie,Stanley Usen,Claire Oluwalana,Stephen Obaro,Martin Weber,Tumani Corrah,Kim Mulholland,Keith Mcadam,Brian Greenwood,Paul Milligan (2005). Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study.
L Moulton,S Chung,J Croll,R Reid,R Weatherholtz,M Santosham (2000). Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population.
Michael Hochberg (2020). Importance of suppression and mitigation measures in managing COVID-19 outbreaks.
Philippe Gautret,Jean-Christophe Lagier,Philippe Parola,Van Hoang,Line Meddeb,Morgane Mailhe,Barbara Doudier,Johan Courjon,Valérie Giordanengo,Vera Vieira,Hervé Tissot Dupont,Stéphane Honoré,Philippe Colson,Eric Chabrière,Bernard La Scola,Jean-Marc Rolain,Philippe Brouqui,Didier Raoult (2020). RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
J Stebbing,A Phelan,I Grin,C Tucker,O Oechsle,D Smith (2020). COVID-19: Combining antiviral and anti-inflammatory treatments.
Y Dong,X Mo,Y Hu,X Qi,F Jiang,Z Jiang (2020). Epidemiology of COVID-19 among children in China.
Lloyd-Smith,J Schreiber,S Kopp,P Getz,W (2005). Super-spreading and the effect of individual variation on disease emergence.
Yang Liu,Rosalind Eggo,Adam Kucharski (2020). Secondary attack rate and superspreading events for SARS-CoV-2.
Juanjuan Zhao,Quan Yuan,Haiyan Wang,Wei Liu,Xuejiao Liao,Yingying Su,Xin Wang,Jing Yuan,Tingdong Li,Jinxiu Li,Shen Qian,Congming Hong,Fuxiang Wang,Yingxia Liu,Zhaoqin Wang,Qing He,Zhiyong Li,Bin He,Tianying Zhang,Shengxiang Ge,Lei Liu,Jun Zhang,Ningshao Xia,Zheng Zhang (2020). Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.
Roman Wölfel,Victor Corman,Wolfgang Guggemos,Michael Seilmaier,Sabine Zange,Marcel Müller,Daniela Niemeyer,Terry Jones,Patrick Vollmar,Camilla Rothe,Michael Hoelscher,Tobias Bleicker,Sebastian Brünink,Julia Schneider,Rosina Ehmann,Katrin Zwirglmaier,Christian Drosten,Clemens Wendtner (2020). Virological assessment of hospitalized patients with COVID-2019.
K To,O Tsang,W Leung (2020). Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
Mha Biswas,L Paiva,De Pinho,Mdr (2014). A SEIR model for control of infectious diseases with constraints.
H Herrmann,J Schwartz (2020). Using network science to propose strategies for effectively dealing with pandemics: The COVID-19 example.
M Fresnadillo-Martínez,E Garcia-Sanchez,E Garcia-Merino,García-Sánchez Je (2013). Mathematical modelling of the propagation of infectious diseases: Where we came from, and where we are going.
Wen Zhang,Yan Zhao,Fengchun Zhang,Qian Wang,Taisheng Li,Zhengyin Liu,Jinglan Wang,Yan Qin,Xuan Zhang,Xiaowei Yan,Xiaofeng Zeng,Shuyang Zhang (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Yang Zhen-Dong,Zhou Gao-Jun,Jin Run-Ming,Liu Zhi-Sheng,Dong Zong-Qi,Xie Xiong,Song Guo-Wei (2020). Clinical and transmission dynamics characteristics of 406 children with coronavirus disease 2019 in China: A review.
Qifang Bi,Yongsheng Wu,Shujiang Mei,Chenfei Ye,Xuan Zou,Zhen Zhang,Xiaojian Liu,Lan Wei,Shaun Truelove,Tong Zhang,Wei Gao,Cong Cheng,Xiujuan Tang,Xiaoliang Wu,Yu Wu,Binbin Sun,Suli Huang,Yu Sun,Juncen Zhang,Ting Ma,Justin Lessler,Tiejian Feng (2020). Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study.
M Gomes,Marcelo Ferreira,Rodrigo Corder,Jessica King,Caetano Souto-Maior,Carlos Penha-Gonçalves,Guilherme Gonçalves,Maria Chikina,Wesley Pegden,Ricardo Aguas (2020). Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold.
Tae Kim,Jennie Johnstone,Mark Loeb (2009). Vaccine herd effect.
Tae Kim (2014). Seasonal influenza and vaccine herd effect.
L Pittet,K Posfay-Barbe (2012). Pneumococcal vaccines for children: a global public health priority.
Fabrice Mougeni,Ance Mangaboula,Bertrand Lell (2020). The potential effect of the African population age structure on COVID-19 mortality.
Andrea Cortegiani,Giulia Ingoglia,Mariachiara Ippolito,Antonino Giarratano,Sharon Einav (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
(2020). COVID-19 reinfection: are we ready for winter?.
Rachel Graham,Eric Donaldson,Ralph Baric (2013). A decade after SARS: strategies for controlling emerging coronaviruses.
Mohammad Ali,Michael Emch,Lorenz Von Seidlein,Mohammad Yunus,David Sack,Malla Rao,Jan Holmgren,John Clemens (2005). Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.
Stanley Plotkin (2008). Vaccines: Correlates of Vaccine‐Induced Immunity.
D Nicola,M Vito,J Linda,B Canio (2020). COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us.
Giuseppe Del Giudice,Jörg Goronzy,Beatrix Grubeck-Loebenstein,Paul-Henri Lambert,Tomas Mrkvan,Jeffrey Stoddard,T Doherty (2017). Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging.
Syed Ahmed,Ahmed Quadeer,Matthew Mckay (2020). Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.
James Colgrove (2016). Vaccine Refusal Revisited — The Limits of Public Health Persuasion and Coercion.
C Metcalf,M Ferrari,A Graham,B Grenfell (2015). Understanding Herd Immunity.
Arturo Casadevall,Liise-Anne Pirofski (2020). The convalescent sera option for containing COVID-19.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Bayode, Michael Tosin. 2021. \u201cProspective Promising Signs of Herd Iimmunity in COVID-19 Transmission Suppression via Vaccination\u201d. Global Journal of Medical Research - C: Microbiology & Pathology GJMR-C Volume 21 (GJMR Volume 21 Issue C1).

More Citation Formats

Select Citation Style:

Download Citation

GJMR Volume 21 Issue C1

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-C Classification NLMC Code: QW 4

Submission ReceivedJune 7, 2021
Peer Review Double Blind
Handling Editor
Accepted July 2, 2021
Published July 15, 2021

Version of record

v1.2

Issue date

March 23, 2021

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 2180

Total Downloads: 978

2026 Trends

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]